SCM
GRCE

Stonepine Capital Management’s Grace Therapeutics GRCE Stock Holding History

Stonepine Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-211,010
Closed -$628K – 88
2025
Q3 		$628K Sell
211,010
-81,490
-28% -$255K 0.51% 36
2025
Q2 		$869K Sell
292,500
-2,050
-0.7% -$5.46K 0.85% 31
2025
Q1 		$666K Buy
+294,550
New +$928K 0.65% 31

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stonepine Capital Management's GRCE Position: Q4 2025 in Review

Stonepine Capital Management sold out of Grace Therapeutics (GRCE) in Q4 2025, closing a stake of 211,010 shares — an estimated $628K sold.

Stonepine Capital Management first reported a position in GRCE in Q1 2025 and held it in 3 quarters. The position peaked at $869K in Q2 2025. 23 funds tracked by Wall St. Rank hold GRCE as of Q4 2025.

  • Stonepine Capital Management reported no remaining Grace Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 211,010 Grace Therapeutics shares in Q4 2025, an estimated $628K.
  • Stonepine Capital Management first reported a position in Grace Therapeutics in Q1 2025 and held it in 3 quarters.
  • Stonepine Capital Management's Grace Therapeutics position peaked at $869K in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.